Kobrynski Lisa
Department of Pediatrics, Emory University, Atlanta, GA, USA.
Biologics. 2012;6:277-87. doi: 10.2147/BTT.S25188. Epub 2012 Aug 24.
Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3-4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.
自20世纪50年代以来，使用人免疫球蛋白替代免疫球蛋白G一直是抗体产生缺陷的原发性免疫缺陷疾病的标准治疗方法。这些患者反复遭受严重感染，导致肺部损伤并缩短寿命。每3至4周静脉注射免疫球蛋白（IVIG）可有效预防严重细菌感染并改善接受治疗患者的生活质量。皮下注射免疫球蛋白（SCIG）在预防感染方面同样有效，与IVIG相比，严重不良反应的发生率更低。众多研究已证明SCIG的耐受性和可接受性，这些研究表明患者的生活质量有所改善，且抗体缺乏患者更倾向于皮下免疫球蛋白治疗。
